Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.

Dix DB, Fernandez CV, Chi YY, Mullen EA, Geller JI, Gratias EJ, Khanna G, Kalapurakal JA, Perlman EJ, Seibel NL, Ehrlich PF, Malogolowkin M, Anderson J, Gastier-Foster J, Shamberger RC, Kim Y, Grundy PE, Dome JS; AREN0532 and AREN0533 study committees.

J Clin Oncol. 2019 Oct 20;37(30):2769-2777. doi: 10.1200/JCO.18.01972. Epub 2019 Aug 26.

PMID:
31449468
2.

Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor.

Ortiz MV, Ahmed S, Burns M, Henssen AG, Hollmann TJ, MacArthur I, Gunasekera S, Gaewsky L, Bradwin G, Ryan J, Letai A, He Y, Naranjo A, Chi YY, LaQuaglia M, Heaton T, Cifani P, Dome JS, Gadd S, Perlman E, Mullen E, Steen H, Kentsis A.

JCI Insight. 2019 Aug 8;4(15). pii: 127098. doi: 10.1172/jci.insight.127098. eCollection 2019 Aug 8.

3.

Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study.

Hont AB, Cruz CR, Ulrey R, O'Brien B, Stanojevic M, Datar A, Albihani S, Saunders D, Hanajiri R, Panchapakesan K, Darko S, Banerjee P, Fortiz MF, Hoq F, Lang H, Wang Y, Hanley PJ, Dome JS, Bollard CM, Meany HJ.

J Clin Oncol. 2019 Sep 10;37(26):2349-2359. doi: 10.1200/JCO.19.00177. Epub 2019 Jul 29.

PMID:
31356143
4.

Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study.

Daw NC, Chi YY, Kim Y, Mullen EA, Kalapurakal JA, Tian J, Khanna G, Geller JI, Perlman EJ, Ehrlich PF, Warwick AB, Grundy PE, Fernandez CV, Dome JS; AREN0321 Study Committee.

Eur J Cancer. 2019 Sep;118:58-66. doi: 10.1016/j.ejca.2019.05.033. Epub 2019 Jul 17.

PMID:
31325873
5.

Reply to L. Xie et al.

Mullen EA, Khanna G, Geller JI, Fernandez CV, Dome JS.

J Clin Oncol. 2019 May 10;37(14):1264-1265. doi: 10.1200/JCO.19.00012. Epub 2019 Mar 15. No abstract available.

PMID:
30875281
6.

A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Children's Oncology Group study.

Armstrong AE, Gadd S, Huff V, Gerhard DS, Dome JS, Perlman EJ.

PLoS One. 2018 Dec 13;13(12):e0208936. doi: 10.1371/journal.pone.0208936. eCollection 2018.

7.

Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.

Mullen EA, Chi YY, Hibbitts E, Anderson JR, Steacy KJ, Geller JI, Green DM, Khanna G, Malogolowkin MH, Grundy PE, Fernandez CV, Dome JS.

J Clin Oncol. 2018 Oct 18:JCO1800076. doi: 10.1200/JCO.18.00076. [Epub ahead of print]

PMID:
30335557
8.

Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.

Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM.

Clin Genitourin Cancer. 2019 Feb;17(1):1-6. doi: 10.1016/j.clgc.2018.09.005. Epub 2018 Sep 12.

PMID:
30287223
9.

Reply to D.M. Green.

Dix DB, Seibel NL, Chi YY, Khanna G, Mullen EA, Geller JI, Kalapurakal JA, Ehrlich PF, Malogolowkin MH, Fernandez CV, Dome JS.

J Clin Oncol. 2018 Sep 13:JCO1800659. doi: 10.1200/JCO.18.00659. [Epub ahead of print] No abstract available.

PMID:
30212299
10.

Outcome of Wilms tumor patients with bone metastasis enrolled on National Wilms Tumor Studies 1-5: A report from the Children's Oncology Group.

Iaboni DSM, Chi YY, Kim Y, Dome JS, Fernandez CV.

Pediatr Blood Cancer. 2019 Jan;66(1):e27430. doi: 10.1002/pbc.27430. Epub 2018 Aug 30.

PMID:
30160355
11.

The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing.

Cajaiba MM, Dyer LM, Geller JI, Jennings LJ, George D, Kirschmann D, Rohan SM, Cost NG, Khanna G, Mullen EA, Dome JS, Fernandez CV, Perlman EJ.

Cancer. 2018 Aug;124(16):3381-3389. doi: 10.1002/cncr.31578. Epub 2018 Jun 15.

12.

Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.

Dix DB, Seibel NL, Chi YY, Khanna G, Gratias E, Anderson JR, Mullen EA, Geller JI, Kalapurakal JA, Paulino AC, Perlman EJ, Ehrlich PF, Malogolowkin M, Gastier-Foster JM, Wagner E, Grundy PE, Fernandez CV, Dome JS.

J Clin Oncol. 2018 Jun 1;36(16):1564-1570. doi: 10.1200/JCO.2017.77.1931. Epub 2018 Apr 16.

13.

Reply to B. Zhang et al.

Fernandez CV, Perlman EJ, Gastier-Foster J, Geller JI, Mullen EA, Ehrlich PF, Dome JS.

J Clin Oncol. 2018 May 10;36(14):1454-1455. doi: 10.1200/JCO.2018.78.0445. Epub 2018 Apr 3. No abstract available.

PMID:
29613833
14.

Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.

Fernandez CV, Mullen EA, Chi YY, Ehrlich PF, Perlman EJ, Kalapurakal JA, Khanna G, Paulino AC, Hamilton TE, Gow KW, Tochner Z, Hoffer FA, Withycombe JS, Shamberger RC, Kim Y, Geller JI, Anderson JR, Grundy PE, Dome JS.

J Clin Oncol. 2018 Jan 20;36(3):254-261. doi: 10.1200/JCO.2017.73.7999. Epub 2017 Dec 6. Erratum in: J Clin Oncol. 2019 Oct 10;37(29):2710.

15.

A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.

Gadd S, Huff V, Walz AL, Ooms AHAG, Armstrong AE, Gerhard DS, Smith MA, Auvil JMG, Meerzaman D, Chen QR, Hsu CH, Yan C, Nguyen C, Hu Y, Hermida LC, Davidsen T, Gesuwan P, Ma Y, Zong Z, Mungall AJ, Moore RA, Marra MA, Dome JS, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Ross N, Gastier-Foster JM, Arold ST, Perlman EJ.

Nat Genet. 2017 Oct;49(10):1487-1494. doi: 10.1038/ng.3940. Epub 2017 Aug 21.

16.

Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group.

Ehrlich P, Chi YY, Chintagumpala MM, Hoffer FA, Perlman EJ, Kalapurakal JA, Warwick A, Shamberger RC, Khanna G, Hamilton TE, Gow KW, Paulino AC, Gratias EJ, Mullen EA, Geller JI, Grundy PE, Fernandez CV, Ritchey ML, Dome JS.

Ann Surg. 2017 Sep;266(3):470-478. doi: 10.1097/SLA.0000000000002356. Erratum in: Ann Surg. 2018 Mar;267(3):e64.

17.

Imaging of renal medullary carcinoma in children and young adults: a report from the Children's Oncology Group.

Sandberg JK, Mullen EA, Cajaiba MM, Smith EA, Servaes S, Perlman EJ, Geller JI, Ehrlich PF, Cost NG, Dome JS, Fernandez CV, Khanna G.

Pediatr Radiol. 2017 Nov;47(12):1615-1621. doi: 10.1007/s00247-017-3926-6. Epub 2017 Jul 8.

18.

Congenital mesoblastic nephroma 50 years after its recognition: A narrative review.

Gooskens SL, Houwing ME, Vujanic GM, Dome JS, Diertens T, Coulomb-l'Herminé A, Godzinski J, Pritchard-Jones K, Graf N, van den Heuvel-Eibrink MM.

Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26437. Epub 2017 Jan 26. Review.

PMID:
28124468
19.

Outcome of patients with intracranial relapse enrolled on national Wilms Tumor Study Group clinical trials.

Venkatramani R, Chi YY, Coppes MJ, Malogolowkin M, Kalapurakal JA, Tian J, Dome JS.

Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26406. Epub 2017 Jan 18.

20.

Comprehensive renal function evaluation in patients treated for synchronous bilateral Wilms tumor.

Interiano RB, McCarville MB, Santos ND, Mao S, Wu J, Dome JS, Kieran K, Williams MA, Brennan RC, Krasin MJ, Green DM, Davidoff AM.

J Pediatr Surg. 2017 Jan;52(1):98-103. doi: 10.1016/j.jpedsurg.2016.10.027. Epub 2016 Oct 27.

21.

Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.

Fernandez CV, Perlman EJ, Mullen EA, Chi YY, Hamilton TE, Gow KW, Ferrer FA, Barnhart DC, Ehrlich PF, Khanna G, Kalapurakal JA, Bocking T, Huff V, Tian J, Geller JI, Grundy PE, Anderson JR, Dome JS, Shamberger RC.

Ann Surg. 2017 Apr;265(4):835-840. doi: 10.1097/SLA.0000000000001716.

22.

Wilms Tumor Predisposition.

Dome JS, Huff V.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2003 Dec 19 [updated 2016 Oct 20].

23.

Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.

Ooms AH, Gadd S, Gerhard DS, Smith MA, Guidry Auvil JM, Meerzaman D, Chen QR, Hsu CH, Yan C, Nguyen C, Hu Y, Ma Y, Zong Z, Mungall AJ, Moore RA, Marra MA, Huff V, Dome JS, Chi YY, Tian J, Geller JI, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Walz AL, van den Heuvel-Eibrink MM, de Krijger RR, Ross N, Gastier-Foster JM, Perlman EJ.

Clin Cancer Res. 2016 Nov 15;22(22):5582-5591. doi: 10.1158/1078-0432.CCR-16-0985. Epub 2016 Oct 4.

24.

The Clinical Relevance of Age at Presentation in Nephroblastoma.

Gooskens SL, Segers H, Pritchard-Jones K, Graf N, Dome JS, van den Heuvel-Eibrink MM.

In: van den Heuvel-Eibrink MM, editor. Wilms Tumor [Internet]. Brisbane (AU): Codon Publications; 2016 Mar. Chapter 2.

25.

Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.

Gratias EJ, Dome JS, Jennings LJ, Chi YY, Tian J, Anderson J, Grundy P, Mullen EA, Geller JI, Fernandez CV, Perlman EJ.

J Clin Oncol. 2016 Sep 10;34(26):3189-94. doi: 10.1200/JCO.2015.66.1140. Epub 2016 Jul 11.

26.

Surgical protocol violations in children with renal tumors provides an opportunity to improve pediatric cancer care: a report from the Children's Oncology Group.

Ehrlich PF, Hamilton TE, Gow K, Barnhart D, Ferrer F, Kandel J, Glick R, Dasgupta R, Naranjo A, He Y, Perlman EJ, Kalapurakal JA, Khanna G, Dome JS, Geller J, Mullen E.

Pediatr Blood Cancer. 2016 Nov;63(11):1905-10. doi: 10.1002/pbc.26083. Epub 2016 May 27.

27.

Pediatric cystic nephromas: distinctive features and frequent DICER1 mutations.

Cajaiba MM, Khanna G, Smith EA, Gellert L, Chi YY, Mullen EA, Hill DA, Geller JI, Dome JS, Perlman EJ.

Hum Pathol. 2016 Feb;48:81-7. doi: 10.1016/j.humpath.2015.08.022. Epub 2015 Oct 28.

28.

MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours.

Perlman EJ, Gadd S, Arold ST, Radhakrishnan A, Gerhard DS, Jennings L, Huff V, Guidry Auvil JM, Davidsen TM, Dome JS, Meerzaman D, Hsu CH, Nguyen C, Anderson J, Ma Y, Mungall AJ, Moore RA, Marra MA, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Gastier-Foster JM, Ross N, Smith MA.

Nat Commun. 2015 Dec 4;6:10013. doi: 10.1038/ncomms10013.

29.

Overall Survival and Renal Function of Patients With Synchronous Bilateral Wilms Tumor Undergoing Surgery at a Single Institution.

Davidoff AM, Interiano RB, Wynn L, Delos Santos N, Dome JS, Green DM, Brennan RC, McCarville MB, Krasin MJ, Kieran K, Williams MA.

Ann Surg. 2015 Oct;262(4):570-6. doi: 10.1097/SLA.0000000000001451.

30.

Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration.

Dome JS, Graf N, Geller JI, Fernandez CV, Mullen EA, Spreafico F, Van den Heuvel-Eibrink M, Pritchard-Jones K.

J Clin Oncol. 2015 Sep 20;33(27):2999-3007. doi: 10.1200/JCO.2015.62.1888. Epub 2015 Aug 24. Review.

31.

The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.

Hu Y, Bobb D, He J, Hill DA, Dome JS.

Cancer Biol Ther. 2015;16(6):949-57. doi: 10.1080/15384047.2015.1040964. Epub 2015 Apr 28.

32.

Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2.

Geller JI, Ehrlich PF, Cost NG, Khanna G, Mullen EA, Gratias EJ, Naranjo A, Dome JS, Perlman EJ.

Cancer. 2015 Jul 15;121(14):2457-64. doi: 10.1002/cncr.29368. Epub 2015 Apr 6.

33.

Reply to Wilms tumor and breast cancer.

Dean JB, Dome JS.

Cancer. 2015 Jun 15;121(12):2100-1. doi: 10.1002/cncr.29281. Epub 2015 Feb 24. No abstract available.

34.

Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors.

Walz AL, Ooms A, Gadd S, Gerhard DS, Smith MA, Guidry Auvil JM, Meerzaman D, Chen QR, Hsu CH, Yan C, Nguyen C, Hu Y, Bowlby R, Brooks D, Ma Y, Mungall AJ, Moore RA, Schein J, Marra MA, Huff V, Dome JS, Chi YY, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Jafari N, Ross N, Gastier-Foster JM, Perlman EJ.

Cancer Cell. 2015 Feb 9;27(2):286-97. doi: 10.1016/j.ccell.2015.01.003. Erratum in: Cancer Cell. 2015 Mar 9;27(3):426. Guidry Auvil, Jamie M [corrected to Guidry Auvil, Jaime M].

35.

Inflammatory myofibroblastic tumor as a second neoplasm after Wilms tumor.

Ortiz MV, Rossi CT, Hill DA, Guzzetta PC, Qureshi F, Dome JS.

Pediatr Blood Cancer. 2015 Jun;62(6):1075-7. doi: 10.1002/pbc.25345. Epub 2014 Dec 11.

PMID:
25504840
36.

Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.

Hu Y, Bobb D, Lu Y, He J, Dome JS.

Cancer Genet. 2014 Sep;207(9):403-11. doi: 10.1016/j.cancergen.2014.09.002. Epub 2014 Sep 16.

PMID:
25441685
37.

Breast cancer in Wilms tumor survivors: new insights into primary and secondary prevention.

Dean JB, Dome JS.

Cancer. 2014 Dec 1;120(23):3598-601. doi: 10.1002/cncr.28906. Epub 2014 Oct 27. No abstract available.

38.

TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.

Maschietto M, Williams RD, Chagtai T, Popov SD, Sebire NJ, Vujanic G, Perlman E, Anderson JR, Grundy P, Dome JS, Pritchard-Jones K.

PLoS One. 2014 Oct 14;9(10):e109924. doi: 10.1371/journal.pone.0109924. eCollection 2014.

39.

Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Children's Oncology Group.

Servaes S, Khanna G, Naranjo A, Geller JI, Ehrlich PF, Gow KW, Perlman EJ, Dome JS, Gratias E, Mullen EA.

Pediatr Radiol. 2015 Feb;45(2):166-72. doi: 10.1007/s00247-014-3138-2. Epub 2014 Aug 19.

40.

Feasibility of using CT volume as a predictor of specimen weight in a subgroup of patients with low risk Wilms tumors registered on COG Study AREN03B2: implications for central venous catheter placement.

Ferrer FA, Herbst KW, Fernandez CV, Khanna G, Dome JS, Naranjo A, Mullen EA, Geller JI, Gratias EJ, Shamberger R, Ritchey M, Ehrlich PF.

J Pediatr Urol. 2014 Oct;10(5):969-73. doi: 10.1016/j.jpurol.2014.02.006. Epub 2014 Mar 15.

41.

Risk stratification for wilms tumor: current approach and future directions.

Dome JS, Perlman EJ, Graf N.

Am Soc Clin Oncol Educ Book. 2014:215-23. doi: 10.14694/EdBook_AM.2014.34.215. Review.

42.

DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma.

Doros LA, Rossi CT, Yang J, Field A, Williams GM, Messinger Y, Cajaiba MM, Perlman EJ, A Schultz K, Cathro HP, Legallo RD, LaFortune KA, Chikwava KR, Faria P, Geller JI, Dome JS, Mullen EA, Gratias EJ, Dehner LP, Hill DA.

Mod Pathol. 2014 Sep;27(9):1267-80. doi: 10.1038/modpathol.2013.242. Epub 2014 Jan 31.

43.

Repeat nephron-sparing surgery for children with bilateral Wilms tumor.

Kieran K, Williams MA, McGregor LM, Dome JS, Krasin MJ, Davidoff AM.

J Pediatr Surg. 2014 Jan;49(1):149-53. doi: 10.1016/j.jpedsurg.2013.09.048. Epub 2013 Oct 5.

PMID:
24439600
44.

Aberrant activation, nuclear localization, and phosphorylation of Yes-associated protein-1 in the embryonic kidney and Wilms tumor.

Murphy AJ, Pierce J, de Caestecker C, Libes J, Neblett D, de Caestecker M, Perantoni AO, Tanigawa S, Anderson JR, Dome JS, Das A, Carroll TJ, Lovvorn HN 3rd.

Pediatr Blood Cancer. 2014 Feb;61(2):198-205. doi: 10.1002/pbc.24788. Epub 2013 Sep 20.

45.

Outcome of patients with Stage II/favorable histology Wilms tumor with and without local tumor spill: a report from the National Wilms Tumor Study Group.

Green DM, Breslow NE, D'Angio GJ, Malogolowkin MH, Ritchey ML, Evans AE, Beckwith JB, Perlman EJ, Shamberger RC, Peterson S, Grundy PE, Dome JS, Thomas PR, Kalapurakal JA.

Pediatr Blood Cancer. 2014 Jan;61(1):134-9. doi: 10.1002/pbc.24658. Epub 2013 Aug 23.

46.

Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.

Gratias EJ, Jennings LJ, Anderson JR, Dome JS, Grundy P, Perlman EJ.

Cancer. 2013 Nov 1;119(21):3887-94. doi: 10.1002/cncr.28239. Epub 2013 Aug 26.

47.

Is adrenalectomy necessary during unilateral nephrectomy for Wilms Tumor? A report from the Children's Oncology Group.

Kieran K, Anderson JR, Dome JS, Ehrlich PF, Ritchey ML, Shamberger RC, Perlman EJ, Green DM, Davidoff AM.

J Pediatr Surg. 2013 Jul;48(7):1598-603. doi: 10.1016/j.jpedsurg.2013.04.019.

48.

Margin status and tumor recurrence after nephron-sparing surgery for bilateral Wilms tumor.

Kieran K, Williams MA, Dome JS, McGregor LM, Krasin MJ, Davidoff AM.

J Pediatr Surg. 2013 Jul;48(7):1481-5. doi: 10.1016/j.jpedsurg.2013.02.033.

PMID:
23895958
49.

Incidence and outcomes of patients with late recurrence of Wilms' tumor.

Malogolowkin M, Spreafico F, Dome JS, van Tinteren H, Pritchard-Jones K, van den Heuvel-Eibrink MM, Bergeron C, de Kraker J, Graf N; COG Renal Tumors Committee and the SIOP Renal Tumor Study Group.

Pediatr Blood Cancer. 2013 Oct;60(10):1612-5. doi: 10.1002/pbc.24604. Epub 2013 Jun 4.

PMID:
23737480
50.

Image based feasibility of renal sparing surgery for very low risk unilateral Wilms tumors: a report from the Children's Oncology Group.

Ferrer FA, Rosen N, Herbst K, Fernandez CV, Khanna G, Dome JS, Mullen E, Gow KW, Barnhart DC, Shamberger RC, Ritchey M, Ehrlich P.

J Urol. 2013 Nov;190(5):1846-51. doi: 10.1016/j.juro.2013.05.060. Epub 2013 May 30.

PMID:
23727411

Supplemental Content

Support Center